See a Demo

Transparent Thinking Blog

TrialAssure cubes divider

CIO of TrialAssure accepted into Forbes Technology Council

by Staff Writer | September 2018

Posted in News
Read More

This week in transparency news: August 25 – September 7, 2018

by Staff Writer | September 2018

Posted in Blog
Read More
trialassure clinical trial transparency news

This week in transparency: August 18 – August 24, 2018

by Staff Writer | August 2018

Posted in Blog
Read More

TrialAssure Partners with Otsuka Pharmaceutical to Provide Clinical Trial Disclosure Reporting System for Global Pipeline

by Staff Writer | August 2018

Posted in News
Read More

This week in transparency news: August 10 – August 17, 2018

by Staff Writer | August 2018

Posted in Blog
Read More

TrialAssure® Announces New Applications in its Product Pipeline to Build The Ultimate Transparency Suite™

by Staff Writer | August 2018

Posted in News
Read More
Outsourcing-Pharma released a State of the Industry report that sheds light on the global pharmaceutical industry. One of the key findings in the report showed that more than half of survey respondents believe that industry initiatives will lead to greater transparency. The report points to a new pilot program launched earlier this year by the FDA to increase transparency. Clinical Trial Transparency Software client feedback

This week in transparency news: August 4 – August 9, 2018

by Staff Writer | August 2018

Posted in Blog
Read More
Should people share their DNA for drug development purposes? – USA Today Many people don’t realize that sharing a DNA sample with Ancestry.com, 23andMe and others can result in their data being shared. However, this week, the companies pledged that they would disclose when data is shared with corporations or the government. With a $300 million investment by GSK in 23andMe, they state that approximately 80 percent of customers have agreed to share their DNA data. This data is being de-identified before it is shared.

This week in transparency news: July 28 – August 3, 2018

by Staff Writer | August 2018

Posted in Blog
Read More
Policy 0070 submissions pending suspension in Europe – DIA Communities Due to EMA’s relocation from London to Amsterdam, the “launch of new procedures (related to clinical data publication under Policy 0070) will be temporarily suspended already as of 1 August 2018,” according to an email shared by Melanie Carr, Head of Stakeholders and Communication Division and Head of Corporate Stakeholders Department ad interim, European Medicines Agency (EMA). It is noted that all redaction proposal packages submitted after July 31st will be temporarily suspended. A press release with full details is said to be released next week.

This week in transparency news: July 21 – July 27, 2018

by Staff Writer | July 2018

Posted in Blog
Read More
Policy 0070 submissions pending suspension in Europe – DIA Communities Due to EMA’s relocation from London to Amsterdam, the “launch of new procedures (related to clinical data publication under Policy 0070) will be temporarily suspended already as of 1 August 2018,” according to an email shared by Melanie Carr, Head of Stakeholders and Communication Division and Head of Corporate Stakeholders Department ad interim, European Medicines Agency (EMA). It is noted that all redaction proposal packages submitted after July 31st will be temporarily suspended. A press release with full details is said to be released next week.

This week in transparency news: July 14 – July 20, 2018

by Staff Writer | July 2018

Posted in Blog
Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Yes, please send me more information about TrialAssure.